Omalizumab (CAT#: TP-097CL)

1. Q 1: What is the primary target of Omalizumab?

   A: Omalizumab targets human immunoglobulin E (IgE), a key player in allergic reactions. By binding to IgE, it prevents it from attaching to its receptors on immune cells, thereby dampening the allergic response.

2. Q 2: What are potential uses for Omalizumab in laboratory settings?

   A: This antibody can be utilized to investigate mechanisms of allergic inflammation, perform binding studies, and in bioassays to test the efficacy of novel therapies targeting IgE-related pathways.

3. Q 3: Can Omalizumab be used as a control in IgE-related assays?

   A: Yes, it can function as a control to evaluate the neutralization or binding capacity of other therapeutic candidates targeting IgE.

4. Q 4: How does Omalizumab help in studying immune cell interactions?

   A: By blocking IgE, it aids in dissecting the roles of mast cells and basophils in allergic and autoimmune responses, contributing to a better understanding of cell signaling and immune regulation.

5. Q 5: What is the role of Omalizumab in signaling pathway analysis?

   A: It serves as a critical tool in dissecting IgE-mediated signal transduction and understanding the broader implications of IgE receptor blockade on immune cell functions.

View the frequently asked questions answered by Creative Biolabs Support.